francisco catedral - the lash & beauty studio LLC

7014 13th avenue, suite 202
brooklyn, new york 11228

NYS Entity Status
ACTIVE

NYS Filing Date
NOVEMBER 19, 2013

NYS DOS ID#
4489176

County
NEW YORK

Jurisdiction
NEW YORK

Registered Agent
UNITED STATES CORPORATION AGENTS, INC.
7014 13TH AVENUE, SUITE 202
BROOKLYN, NEW YORK, 11228

NYS Entity Type
DOMESTIC LIMITED LIABILITY COMPANY

Name History
2013 - FRANCISCO CATEDRAL - THE LASH & BEAUTY STUDIO LLC









Buffer



submit to reddit

Telephone
n/a

Fax
n/a

Website
n/a

Email address
n/a

LinkedIn
n/a

Facebook
n/a

Google+
n/a

Twitter
n/a

Pinterest
n/a

Instagram
n/a



  • AROUND THE WEB

  • Bio Roundup: ASCO Digested, Juliet Unveiled, PTC Slated & More
    By Alex Lash - Friday Jun 9, 2017

    The New York Times Magazine wrote a few weeks ago about the extraordinary metabolic changes in a python after it gulps down a 50,000 calorie meal. The biomedical world was like a postprandial python this week; after extending its maw around the supersized meal of news and data from the American Society for Clinical Oncology […]

    Source: Xconomy New York
  • ASCO Roundup: Checkpoint Combos, Tumor Profiling, Financial Toxicity
    By Alex Lash - Tuesday Jun 6, 2017

    [Note: Ben Fidler coauthored this report.] The American Society of Clinical Oncology conference is wrapping up, and the closely watched medical meeting-slash-hype machine produced its usual array of data. There were a few big business-focused “horse race” stories—one company’s stumble was another company’s gain—but much of the news consisted of mid-trial updates that companies produce […]

    Source: Xconomy New York
  • Cyclist Killed by Bus in New York’s First Citi Bike Fatality
    By MATTHEW HAAG and HANNAH ALANI - Tuesday Jun 13, 2017

    Dan Hanegby of Brooklyn fell under a bus’s tires in Chelsea. He worked for Credit Suisse and was once the top-ranked tennis player in Israel.

    Source: NYT > Home Page
  • Amgen’s Heart Data Don’t Impress Drug-Price Evaluation Group
    By Alex Lash - Tuesday Jun 13, 2017

    The drug-price evaluator that the drug companies love to hate has weighed in again, this time casting a skeptical eye on the price of a next-generation heart medicine from Amgen (NASDAQ: AMGN). The group known as ICER, which stands for Institute for Clinical and Economic Review, released a report today that said Amgen’s evolocumab (Repatha) […]

    Source: Xconomy New York
  • Fit City: Taking Night-Life Cue, Gyms Lower the Lights
    By TATIANA BONCOMPAGNI - Tuesday Jun 13, 2017

    Cycling, boxing and running studios, as well as some full-service gyms, are using sophisticated lighting systems to heighten the exercise experience.

    Source: NYT > Home Page
  • Neighborhood Joint: Staubitz Market in Brooklyn: 100 Years of Sawdust, Steaks and Chops
    By ANDREW COTTO - Wednesday Jun 14, 2017

    A display contains frozen items, and the shelves are stocked with jars and cans. But there’s just one reason to visit this Boerum Hill business: meat.

    Source: NYT > Home Page
  • Pride 2017: New York’s L.G.B.T.Q. Story Began Well Before Stonewall
    By LIAM STACK - Monday Jun 19, 2017

    The gay bar’s 1969 patron-police battle, hailed as a starting point, actually followed many events in the city, now mapped in a sites project.

    Source: NYT > Home Page
  • San Francisco Could Be First City To Ban Sale Of Flavored Liquid Nicotine
    By Ashlee Kieler - Thursday Jun 22, 2017

    Last fall, the American Academy of Pediatrics called for a ban on flavored tobacco products. Now, one city is poised to do just that: San Francisco took steps this week to become the first city to approve a sales ban on flavored vaping liquids in a bid to prevent young adults from becoming addicted to the products.   The Associated …

    Source: The Consumerist